Rhythm Pharmaceuticals, Inc. (BMV:RYTM)

Market Cap	106.80B +61.4%
Revenue (ttm)	3.42B +45.8%
Net Income	-3.64B
EPS	-55.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	599
Average Volume	3,380
Open	1,866.76
Previous Close	2,025.00
Day's Range	1,866.76 - 1,866.76
52-Week Range	1,800.00 - 2,025.00
Beta	n/a
RSI	78.94
Earnings Date	Feb 26, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 414
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: RYTM

Financial Performance

In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.

Financial numbers in USD